InsidersTradesSigma
CareDx, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the CareDx, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, CareDx, Inc. has recorded 372 insider filings. Market capitalisation: €2bn. The latest transaction was disclosed on 17 July 2026 (Levée d'options). Among the most active insiders: Novack Jeffrey Adam. All data is openly available.
372
Insider Decl.
n/a
Thresholds
€212,983
2 ops.
Buy Volume
€12m
62 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CareDx, Inc. Buy (bullish), based on 5 analysts. Average price target: US$33.00.
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,752 of 27,759 companies
40.3
score / 100
Value39
Quality42
FCF yld1.8%
Earn yld-1.1%
EV/EBITDA·
ROE-2.4%
Gross mgn68%
Net mgn-5.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 July 2026
Declarations372 total
5,125 shares@ US$7.960.0026% mcap2.4% of flowCommon StockSEC:0001855608-26-000004:2
28,679 shares@ US$36.14450.067% mcap62.2% of flowCommon StockSEC:0001855608-26-000004:3
100 shares@ US$36.550.0002% mcap0.2% of flowCommon StockSEC:0001855608-26-000004:4
118,000 shares@ US$8.200.063% mcap10.6% of flowCommon StockSEC:0001781127-26-000012:0
50,000 shares@ US$36.11410.12% mcap19.8% of flowCommon StockSEC:0001781127-26-000012:1
68,000 shares@ US$39.01370.17% mcap29.2% of flowCommon StockSEC:0001781127-26-000012:2
7,606 shares@ US$20.560.010% mcap9.4% of flowCommon StockSEC:0001855608-26-000004:0
16,048 shares@ US$14.190.015% mcap13.7% of flowCommon StockSEC:0001855608-26-000004:1
28,779 shares@ US$29.750.056% mcap75.7% of flowCommonSEC144:0001950047-26-007167
118,000 shares@ US$29.750.23% mcap97.1% of flowCommonSEC144:0001950047-26-007172
1,746 shares0Common StockSEC:0001366412-26-000006:0
8,511 shares@ US$29.250.017% mcap16.0% of flowCommon StockSEC:0001781127-26-000011:0
706 shares@ US$8.200.0003% mcap0.4% of flowCommon StockSEC:0001781127-26-000010:0
13,618 sharesCommon StockSEC:0001781127-26-000010:1
15,676 sharesCommon StockSEC:0001781127-26-000010:2
100 sharesCommon StockSEC:0001781127-26-000010:3
100 sharesCommon StockSEC:0001781127-26-000010:4
39,900 sharesCommon StockSEC:0001781127-26-000010:5
39,900 sharesCommon StockSEC:0001781127-26-000010:6
17,683 sharesCommon StockSEC:0001781127-26-000009:0
9,795 sharesCommon StockSEC:0001329646-26-000001:0
9,795 sharesCommon StockSEC:0001180466-26-000004:0
9,795 sharesCommon StockSEC:0001339358-26-000002:0
9,795 sharesCommon StockSEC:0001366412-26-000004:0
9,795 sharesCommon StockSEC:0001621899-26-000001:0
25 of 372 declarations
关于 CareDx, Inc.
CareDx, Inc.（股票代码：CDNA）是一家在美国纳斯达克上市的美国精准医疗公司，专注于改善移植患者的预后。其商业模式围绕移植诊断、实验室产品、数字健康工具和患者支持服务构建。实际上，CareDx 旨在为临床医生、移植中心和患者提供在整个移植过程中，尤其是在移植后监测阶段，更好的可见性。公司总部位于加利福尼亚州布里斯班，在内布拉斯加州奥马哈和瑞典斯德哥尔摩设有其他主要运营机构。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)） CareDx 成立于 2000 年，已从一家专注于诊断的公司发展成为一个更广泛的移植解决方案平台。其商业化的检测产品组合包括 AlloSure Kidney、AlloMap Heart、AlloSure Heart、HeartCare 和 AlloSure Lung，用于监测肾脏、心脏和肺移植受者。除了这些分子检测，该公司还提供数字健康解决方案和患者服务，旨在改善护理协调、工作流程效率和患者体验。这种综合方法在专业市场中非常重要，因为临床证据、报销和医生采纳是关键的竞争驱动因素。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)） 从竞争角度来看，CareDx 在医疗保健领域的一个利基但具有战略吸引力的细分市场中运营。移植监测市场受到对非侵入性、临床验证工具的需求以及与移植中心的牢固关系的影响。CareDx 通过将分子诊断与数字能力相结合来区分自己，而不是依赖单一产品模式。其地理足迹主要集中在北美和欧洲，通过运营和商业基础设施，而其客户群涵盖移植项目和医疗保健利益相关者。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)） 最近的发展对投资者来说值得关注。CareDx 报告 2025 财年全年收入为 380 million 美元，同比增长 14%，这得益于检测服务、患者和数字解决方案以及产品收入的增长。2026 年 4 月，该公司宣布达成协议，将其瑞典子公司 CareDx AB 的股份及其试剂盒实验室产品业务相关的某些资产出售给 Eurobio Scientific，作价 170 million 美元现金，这表明可能进行投资组合简化，并更加专注于核心移植诊断和数字产品。对于讲法语的投资者而言，CDNA 因此是一家在美国纳斯达克上市的医疗保健公司，拥有专业的移植特许经营权、全球运营足迹以及最近可能重塑其业务组合的战略举措。（[investors.caredx.com](https://investors.caredx.com/news/news-details/2026/CareDx-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai)）
